Richter's Syndrome
Showing 1 - 25 of >10,000
Chronic Lymphocytic Leukemia, Richter Syndrome Trial in United States (Duvelisib, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Richter Syndrome
-
Miami, Florida
- +6 more
Jan 6, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome Trial in Italy, United Kingdom, United States
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +3 more
-
Boston, Massachusetts
- +11 more
Nov 23, 2022
Richter Syndrome, Chronic Lymphocytic Leukemia Trial in New York (Polatuzumab Vedotin, Rituximab, Etoposide)
Recruiting
- Richter Syndrome
- Chronic Lymphocytic Leukemia
- Polatuzumab Vedotin
- +5 more
-
New York, New YorkWeill Cornell Medicine
Dec 19, 2022
Richter's Syndrome Trial in Israel (Obinutuzumab with Ibrutinib and Venetoclax)
Recruiting
- Richter's Syndrome
- Obinutuzumab with Ibrutinib and Venetoclax
-
Haifa, Israel
- +3 more
Dec 6, 2021
Mediastinal Large B-cell Lymphoma, Richter Syndrome Trial (Pembrolizumab)
Completed
- Mediastinal Large B-cell Lymphoma
- Richter Syndrome
- Pembrolizumab
- (no location specified)
Oct 21, 2021
Relapsed/Refractory Chronic Lymphocytic Leukemia, Richter's Syndrome Trial in Worldwide (Epcoritamab)
Recruiting
- Relapsed/Refractory Chronic Lymphocytic Leukemia
- Richter's Syndrome
- Epcoritamab
-
Tuscaloosa, Alabama
- +22 more
Jun 15, 2022
Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,
Recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Acalabrutinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic
Not yet recruiting
- Recurrent Transformed Chronic Lymphocytic Leukemia
- +7 more
- Biospecimen Collection
- +9 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
May 15, 2023
Hematopoietic and Lymphoid Cell Tumor, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in
Not yet recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 10, 2022
Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial
Not yet recruiting
- Aggressive B-Cell Non-Hodgkin's Lymphoma
- +4 more
- (no location specified)
Dec 16, 2022
Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)
Recruiting
- Chronic Lymphocytic Leukemia
- +6 more
- Copanlisib
- Nivolumab
-
Duarte, California
- +2 more
Mar 9, 2022
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome Trial
Not yet recruiting
- Recurrent Transformed Chronic Lymphocytic Leukemia
- +2 more
- Biopsy
- +10 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 3, 2023
Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic
Recruiting
- Chronic Lymphocytic Leukemia
- +4 more
- Atezolizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Sep 30, 2021
Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,
Completed
- Loss of Chromosome 17p
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Mar 4, 2022
Ovulation Induction, Polycystic Ovary Syndrome, Clomiphene Trial in Ghent (Myo-inositol, Clomiphene Citrate)
Terminated
- Ovulation Induction
- +3 more
- Myo-inositol
- Clomiphene Citrate
-
Ghent, BelgiumUniversity Hospital
Dec 16, 2022
B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma Trial in Valhalla (Polatuzumab vedotin)
Recruiting
- B-cell Lymphoma
- +8 more
- Polatuzumab vedotin
-
Valhalla, New YorkNew York Medical Center
Oct 29, 2021
Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in
Completed
- Relapsed or Refractory Haematological Malignancies Including
- +10 more
-
Aachen, Germany
- +11 more
Oct 21, 2021
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)
Active, not recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +5 more
- Atezolizumab
- +9 more
-
Duarte, California
- +3 more
Nov 17, 2022
Anemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma Trial in Portland (drug, other, biological)
Completed
- Anemia
- +13 more
- Entospletinib
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Apr 29, 2021